Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. 2005

Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
Department of Pharmacology, Tohoku University School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan. jalalizadi2002@yahoo.com

Orexins are neuropeptides that are mostly expressed in the posterior and lateral hypothalamus, and related to the central control of appetite, arousal, and antinociception. Orexin neurons projected to the tuberomammillary nucleus and orexins may release histamine from the histamine neurons in this nucleus. Histamine is known to cause hypernociception. The roles of histamine H1 and H2 receptors in the orexin A-induced antinociception, however, have not been clarified yet. Here we studied the effects of histamine H1 and H2 receptors on orexin A-produced antinociception using histamine receptor knockout mice in four assays of nociception; the hot-plate, the tail-flick, the tail-pressure and the capsaicin tests. Furthermore we studied effects of histamine H1 and H2 receptor antagonists on orexin A-produced antinociception in C57BL/6 mice. The antinociceptive effects of i.c.v. orexin A were greater in histamine H1 receptor or H2 receptor knockout mice than in the wild-type mice in all four assays of pain. Furthermore, treatment of C57BL/6 mice with a combination of i.c.v. orexin A and d-chlorpheniramine (a histamine H1 receptor antagonist) or cimetidine (a histamine H2 receptor antagonist) showed a greater antinociception than i.c.v. orexin A alone in all four assays. These findings suggest the possibility that orexin A may activate H1 and H2 receptors in the supraspinal levels through the release of histamine from neurons, which might attenuate the antinociceptive effects of orexin A. Thus, the blocking of the histamine H1 or H2 receptor may produce antinociception and enhance the orexin A-induced antinociception.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010147 Pain Measurement Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies. Analgesia Tests,Analogue Pain Scale,Formalin Test,McGill Pain Questionnaire,Nociception Tests,Pain Assessment,Pain Intensity,Pain Severity,Tourniquet Pain Test,Visual Analogue Pain Scale,Analog Pain Scale,Assessment, Pain,McGill Pain Scale,Visual Analog Pain Scale,Analgesia Test,Analog Pain Scales,Analogue Pain Scales,Formalin Tests,Intensity, Pain,Measurement, Pain,Nociception Test,Pain Assessments,Pain Intensities,Pain Measurements,Pain Questionnaire, McGill,Pain Scale, Analog,Pain Scale, Analogue,Pain Scale, McGill,Pain Severities,Pain Test, Tourniquet,Questionnaire, McGill Pain,Scale, Analog Pain,Scale, Analogue Pain,Scale, McGill Pain,Severity, Pain,Test, Analgesia,Test, Formalin,Test, Nociception,Test, Tourniquet Pain,Tests, Nociception,Tourniquet Pain Tests
D011969 Receptors, Histamine H1 A class of histamine receptors discriminated by their pharmacology and mode of action. Most histamine H1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (From Biochem Soc Trans 1992 Feb;20(1):122-5) H1 Receptor,Histamine H1 Receptors,H1 Receptors,Histamine H1 Receptor,Receptors, H1,H1 Receptor, Histamine,H1 Receptors, Histamine,Receptor, H1,Receptor, Histamine H1
D011970 Receptors, Histamine H2 A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H2 receptors act via G-proteins to stimulate ADENYLYL CYCLASES. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (From Biochem Soc Trans 1992 Feb;20(1):122-5) Histamine H2 Receptors,H2 Receptors,Receptors, H2,H2 Receptors, Histamine
D002744 Chlorpheniramine A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE. Chlorphenamine,Chlorprophenpyridamine,Aller-Chlor,Antihistaminico Llorens,Chlo-Amine,Chlor-100,Chlor-Trimeton,Chlor-Tripolon,Chlorpheniramine Maleate,Chlorpheniramine Tannate,Chlorpro,Chlorspan 12,Chlortab-4,Cloro-Trimeton,Efidac 24,Kloromin,Piriton,Teldrin,Maleate, Chlorpheniramine,Tannate, Chlorpheniramine
D000068797 Orexins Neuropeptide hormones that play a role in regulating a variety of behavioral and physiological processes in response to motivational stimuli. Hypocretin,Orexin,Hypocretin-1,Hypocretin-2,Hypocretins,Orexin-A,Orexin-B,Hypocretin 1,Hypocretin 2,Orexin A,Orexin B
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
June 2002, Neuropharmacology,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
April 1992, European journal of pharmacology,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
June 1993, The Journal of pharmacology and experimental therapeutics,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
April 1999, Neuropeptides,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
April 1987, Agents and actions,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
October 2005, European journal of pharmacology,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
December 2005, Psychopharmacology,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
December 1990, Methods and findings in experimental and clinical pharmacology,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
November 1995, Neuropeptides,
Jalal Izadi Mobarakeh, and Kazuhiro Takahashi, and Shinobu Sakurada, and Seiji Nishino, and Hiroyuki Watanabe, and Motohisa Kato, and Nasser Naghdi, and Kazuhiko Yanai
April 1999, Neuropeptides,
Copied contents to your clipboard!